Beta Drugs Limited
Beta Drugs Board will convene on May 14, 2026, to consider and approve the audited standalone and consolidated financial results for the financial year ended March 31, 2026.
May 11 2026 16:05:00
Beta Drugs Limited
Beta Drugs board of directors will convene on May 14, 2026, to discuss and approve the financial results for the financial year ended March 31, 2026. This meeting is crucial for reviewing the company's annual performance.
May 11 2026 16:05:00
Beta Drugs Limited (BETA)
Beta Drugs Limited allotted 283,668 equity shares on April 25, 2026, via a preferential issue. This increased the company's paid-up capital to ₹10.42 crores, with shares issued at ₹1,712.49 each to 33 investors.
Apr 25 2026 14:04:00
Beta Drugs Limited (BETA)
Beta Drugs' board approved the allotment of 2,83,668 equity shares. These shares, priced at ₹1,712.49 each (including a premium of ₹1,702.49), are issued to facilitate the acquisition of Nivian Lifesciences Private Limited.
Apr 25 2026 13:04:00
Beta Drugs Limited (BETA)
Beta Drugs expands international market access with key regulatory milestones in Azerbaijan and the Philippines. The company expects GMP approval in 1-2 months for Azerbaijan and secured product registrations for 2 generic brands in the Philippines, strengthening export sales.
Apr 22 2026 09:04:00
Beta Drugs Limited (BETA)
Beta Drugs expands international market access with key regulatory milestones in Azerbaijan and the Philippines. The company expects GMP approval in 1-2 months for Azerbaijan and secured product registrations for 2 generic brands in the Philippines, strengthening export sales.
Apr 22 2026 09:04:00
Read More